Back
Top 3%
9.1%
Top 62%
8.8%
Top 0.3%
8.8%
Top 40%
6.3%
Top 16%
6.3%
Top 0.1%
5.8%
Top 3%
5.8%
Top 2%
5.8%
Top 0.7%
3.8%
Top 0.8%
3.8%
Top 2%
3.1%
Top 23%
1.9%
Top 50%
1.9%
Top 0.7%
1.8%
Top 3%
1.1%
Top 16%
0.9%
Top 7%
0.7%
Top 25%
0.7%
Top 6%
0.7%
Top 9%
0.7%
Top 14%
0.7%
Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance Study
2025-12-29
oncology
Title + abstract only
View on medRxiv
Show abstract
This study aimed to identify drugs disproportionately reported with malignant neoplasm progression, an uncommon but clinically important endpoint, using large spontaneous reporting systems. Public reports were analyzed from the FDA Adverse Event Reporting System (FAERS; 2004Q1-2024Q4) and the Japanese Adverse Drug Event Report database (JADER; 2004-2024). Cases were defined using MedDRA Preferred Terms for malignant neoplasm/tumour progression, and reports in which progression was recorded as an...
Predicted journal destinations
1
Cancers
57 training papers
2
PLOS ONE
1737 training papers
3
JAMA Network Open
125 training papers
4
Scientific Reports
701 training papers
5
Nature Communications
483 training papers
6
Cancer Medicine
17 training papers
7
Frontiers in Oncology
34 training papers
8
Clinical Cancer Research
22 training papers
9
Clinical Pharmacology & Therapeutics
19 training papers
10
BMC Cancer
21 training papers
11
British Journal of Cancer
22 training papers
12
eLife
262 training papers
13
BMJ Open
553 training papers
14
Journal of Clinical Epidemiology
29 training papers
15
Communications Medicine
63 training papers
16
Proceedings of the National Academy of Sciences
100 training papers
17
Diagnostics
36 training papers
18
Frontiers in Medicine
99 training papers
19
Journal of Clinical Investigation
50 training papers
20
PeerJ
46 training papers
21
iScience
74 training papers